EA202092459A1 - Гибридные белки интерлейкина 12, композиции и способы терапевтического применения, которые их включают - Google Patents

Гибридные белки интерлейкина 12, композиции и способы терапевтического применения, которые их включают

Info

Publication number
EA202092459A1
EA202092459A1 EA202092459A EA202092459A EA202092459A1 EA 202092459 A1 EA202092459 A1 EA 202092459A1 EA 202092459 A EA202092459 A EA 202092459A EA 202092459 A EA202092459 A EA 202092459A EA 202092459 A1 EA202092459 A1 EA 202092459A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compositions
methods
interleukin
therapeutic application
hybrid proteins
Prior art date
Application number
EA202092459A
Other languages
English (en)
Russian (ru)
Inventor
Ян-Синь Фу
Хуа Пэн
Диюань Сюэ
Original Assignee
Иммьюн Таргетинг Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Иммьюн Таргетинг Инк. filed Critical Иммьюн Таргетинг Инк.
Publication of EA202092459A1 publication Critical patent/EA202092459A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EA202092459A 2018-04-25 2019-04-24 Гибридные белки интерлейкина 12, композиции и способы терапевтического применения, которые их включают EA202092459A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201810376920.1A CN110396133B (zh) 2018-04-25 2018-04-25 一种以白介素12为活性成分的融合蛋白型药物前体
PCT/US2019/028933 WO2019209965A2 (en) 2018-04-25 2019-04-24 Interleukin 12 fusion proteins, and compositions and therapeutic methods thereof

Publications (1)

Publication Number Publication Date
EA202092459A1 true EA202092459A1 (ru) 2021-06-15

Family

ID=68294664

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202092459A EA202092459A1 (ru) 2018-04-25 2019-04-24 Гибридные белки интерлейкина 12, композиции и способы терапевтического применения, которые их включают

Country Status (9)

Country Link
US (1) US12473337B2 (https=)
JP (2) JP2021521822A (https=)
KR (1) KR20210024446A (https=)
CN (2) CN110396133B (https=)
AU (1) AU2019261411B2 (https=)
BR (1) BR112020021791A2 (https=)
CA (1) CA3097995A1 (https=)
EA (1) EA202092459A1 (https=)
WO (1) WO2019209965A2 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020530280A (ja) 2017-07-03 2020-10-22 トルク セラピューティクス， インコーポレイテッド 免疫刺激性融合分子およびその使用
WO2020023702A1 (en) 2018-07-25 2020-01-30 AskGene Pharma, Inc. Novel il-21 prodrugs and methods of use thereof
CN113710229B (zh) 2019-02-25 2026-01-06 芝加哥大学 用与抗炎剂连接的ecm亲和肽治疗炎症性和自身免疫性病症的方法和组合物
CA3141626A1 (en) 2019-06-12 2020-12-17 AskGene Pharma, Inc. Novel il-15 prodrugs and methods of use thereof
BR112022001320A2 (pt) * 2019-07-25 2022-04-12 Univ Chicago Composições e métodos compreendendo agentes terapêuticos ativados por protease
CA3165927A1 (en) 2020-01-11 2021-07-15 AskGene Pharma, Inc. Novel masked cytokines and methods of use thereof
JP7771076B2 (ja) * 2020-04-01 2025-11-17 エクシリオ デベロップメント， インコーポレイテッド マスクされたｉｌ－１２サイトカイン及びその切断産物
WO2022115865A2 (en) * 2020-11-25 2022-06-02 Xilio Development, Inc. Tumor-specific cleavable linkers
JP2023553692A (ja) * 2020-12-18 2023-12-25 エフ． ホフマン－ラ ロシュ アーゲー 標的治療のための前駆体タンパク質及びキット
MX2023011268A (es) 2021-03-24 2023-12-14 Alkermes Inc Anticuerpos upar y proteínas de fusión con estos.
WO2022226073A1 (en) * 2021-04-21 2022-10-27 Cue Biopharma, Inc. Mhc class ii t-cell modulatory polypeptides and methods of use thereof
AU2022314734A1 (en) 2021-07-19 2024-02-08 Regeneron Pharmaceuticals, Inc. Il12 receptor agonists and methods of use thereof
CA3234552A1 (en) 2021-10-20 2023-04-27 Synthekine, Inc. Heterodimeric fc cytokines and uses thereof
IL322055A (en) * 2023-01-13 2025-09-01 Regeneron Pharma IL12 receptor agonists and methods of using them
CN121263432A (zh) 2023-04-12 2026-01-02 上海康抗生物技术有限公司 包含掩蔽型白介素12的多功能分子及使用方法
TW202523680A (zh) * 2023-12-07 2025-06-16 大陸商上海藥明生物技術有限公司 針對ｉｌ－１２受體的異二聚體蛋白
WO2025256578A1 (zh) * 2024-06-12 2025-12-18 龙启生物制药(杭州)有限公司 Treg细胞靶向IL12融合蛋白及其制备、治疗方法
WO2026020161A1 (en) * 2024-07-19 2026-01-22 Cytomx Therapeutics, Inc. Activatable il-12 constructs and related compositions and methods

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
EP0939121B2 (de) 1989-09-12 2007-12-26 AHP Manufacturing B.V. TFN-bindende Proteine
ATE311895T1 (de) 1992-05-26 2005-12-15 Immunex Corp Neue zytokine die cd30 binden
AU1407997A (en) * 1995-12-01 1997-06-19 Beth Israel Hospital Il-12 p40 subunit fusion polypeptides and uses thereof
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
CA2275183A1 (en) 1996-12-20 1998-07-02 Amgen Inc. Ob fusion protein compositions and methods
ES2590912T3 (es) * 1997-12-08 2016-11-24 Merck Patent Gmbh Proteínas de fusión heterodiméricas útiles para inmunoterapia dirigida y estimulación general del sistema inmunitario
US7754855B1 (en) 1999-07-13 2010-07-13 Bolder Biotechnology, Inc. Immunoglobulin fusion proteins
EP1418184A1 (en) * 2002-11-08 2004-05-12 Cell Center Cologne GmbH Recombinant fusion protein consisting of the p40 and p35 subunits of IL-12 and a ScFv and use thereof
WO2005037867A1 (en) 2003-10-15 2005-04-28 Pdl Biopharma, Inc. ALTERATION OF Fc-FUSION PROTEIN SERUM HALF-LIVES BY MUTAGENESIS OF POSITIONS 250, 314 AND/OR 428 OF THE HEAVY CHAIN CONSTANT REGION OF IG
JP4718274B2 (ja) 2005-08-25 2011-07-06 東京エレクトロン株式会社 半導体製造装置，半導体製造装置の流量補正方法，プログラム
EP1969000A2 (en) 2005-12-06 2008-09-17 Centre National de la Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
MX387323B (es) * 2014-02-19 2025-03-18 Merck Patent Gmbh Il-12 dirigida al cáncer en combinación con il-7 para usarse en el tratamiento de cáncer.
CN105543279A (zh) * 2014-10-30 2016-05-04 常州卡斯比生物科技有限公司 一种防治辐射线损伤、肿瘤治疗的IL-12/Fc融合蛋白的制备方法及其药剂
CN104628870A (zh) * 2015-02-04 2015-05-20 中国药科大学 一种人IL12Rβ1-CHR蛋白及其Fc融合蛋白
CN105218682B (zh) * 2015-10-26 2019-05-07 杨晶 经il-12/cd62l融合蛋白改造的肿瘤治疗剂及其制法和用途
EP3184548A1 (en) * 2015-12-23 2017-06-28 Miltenyi Biotec GmbH Chimeric antigen receptor with cytokine receptor activating or blocking domain
WO2018030806A1 (ko) * 2016-08-10 2018-02-15 아주대학교산학협력단 항체 중쇄불변부위 이종이중체에 융합된 사이토카인 및 이를 포함하는 약제학적 조성물
US10696722B2 (en) * 2016-08-10 2020-06-30 Ajou University Industry-Academic Cooperation Foundation Heterodimeric Fc-fused cytokine and pharmaceutical composition comprising the same

Also Published As

Publication number Publication date
JP2025032113A (ja) 2025-03-11
BR112020021791A2 (pt) 2021-02-23
KR20210024446A (ko) 2021-03-05
JP2021521822A (ja) 2021-08-30
EP3810639A2 (en) 2021-04-28
US20220162280A1 (en) 2022-05-26
CA3097995A1 (en) 2019-10-31
CN112638938A (zh) 2021-04-09
WO2019209965A2 (en) 2019-10-31
WO2019209965A3 (en) 2019-12-05
AU2019261411A1 (en) 2020-11-26
CN110396133B (zh) 2021-07-23
AU2019261411B2 (en) 2024-11-14
CN110396133A (zh) 2019-11-01
US12473337B2 (en) 2025-11-18

Similar Documents

Publication Publication Date Title
EA202092459A1 (ru) Гибридные белки интерлейкина 12, композиции и способы терапевтического применения, которые их включают
MX2021013126A (es) Variantes de il-15 y usos de las mismas.
EA201992765A1 (ru) Белки на основе антител с привитым цитокином и способы их применения в лечении рака
UA130113C2 (uk) Мутеїн інтерлейкіну-21
JOP20220079A1 (ar) بروتين ربط متعددة الخصوصية لمعالجة السرطان
ZA202004730B (en) Anti-claudin 18.2 antibodies and uses thereof
EA201992131A1 (ru) Высокоаффинные специфичные к mage-a1 tcr и их применение
WO2021021979A3 (en) Hdac6 inhibitors and uses thereof
EA202090372A1 (ru) Универсальные соединения авт и их применение
EA202190453A1 (ru) Полиспецифические связывающие белки, которые связываются с her2, nkg2d и cd16, и способы их применения
EA202092086A1 (ru) Ингибиторы аргиназы
EA202090401A1 (ru) Анти-tim-3 антитела и их применение
EA201792573A1 (ru) Триспецифические связанные белки и способы их применения
EA202192888A1 (ru) Соединения и способы нацеливания на тау человека
EA202191769A1 (ru) Тубулизины и конъюгаты белок-тубулизин
EA201892548A1 (ru) Антитела к альфа-синуклеину и их применение
MX2024005705A (es) Composiciones de liquidos ionicos.
EA201791535A1 (ru) Новое соединение 4'-тионуклеозида, а также способ его получения, его фармацевтическая композиция и применение
CL2022003715A1 (es) Tubulisinas y conjugados de proteinas-tubulisina
EA202092162A1 (ru) Антитела против cxcl13 для лечения аутоиммунных заболеваний и рака
EA202092125A1 (ru) Антитела против рецептора фолата 1 и их применения
MX2023010711A (es) Fenalquilaminas y métodos de preparación y uso de las mismas.
EA202191058A1 (ru) Антитела против муцина-16 и способы их применения
EA202192488A1 (ru) Антитела против tsg-6 и их применения
MX2021008507A (es) Moleculas que se unen al receptor leucocitario similar a inmunoglobulina subfamilia b miembro 3 (lilrb3) y usos para las mismas.